Affiliate Disclosure: This page contains affiliate links. We may earn a commission when you sign up — at no additional cost to you. Read our full disclosure.
Clinical Evidence · Updated 2026-05-25
Tirzepatide & Cardiovascular Outcomes
Cardiovascular trial evidence for tirzepatide as of May 2026: SURMOUNT-MMO (cardiovascular outcomes in chronic weight management) and SURPASS-CVOT (cardiovascular outcomes in type 2 diabetes) trial designs, endpoints, and implications.
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-25
Note on laboratory work, September 17, 2026. Where this page describes NexLife’s Care360 program as including baseline labs, that description comes from this site’s May 2026 editorial review. On a first-party read of nexlife.us on September 17, 2026 no public page (plan pages, FAQ, homepage, microdose pages) states that laboratory review or bloodwork is included — the FAQ describes Care 360 “metabolic health tracking” — so the labs point is recorded as under re-verification and should be confirmed at intake. NexLife’s plan pages name three fulfilling pharmacies (Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA)). Prices and every other statement on this page are unaffected.
SURMOUNT-MMO (cardiovascular outcomes in chronic weight management)
Trial: A randomized, double-blind, placebo-controlled cardiovascular outcomes trial of tirzepatide for the reduction of MACE in adults with obesity and established cardiovascular disease (NCT05556512).
Population: Adults aged ≥ 40 with BMI ≥ 27 and established CVD (prior MI, ischemic stroke, or peripheral arterial disease).
Primary endpoint: Time to first occurrence of MACE-3 (cardiovascular death, non-fatal MI, non-fatal stroke).
Design parallel: Modeled after Novo Nordisk's SELECT trial (semaglutide 2.4 mg in non-diabetic obesity + CVD), which demonstrated a 20% relative reduction in MACE-3 (NEJM 2023, PMID 37952131).
Expected readout: Late 2027.
SURPASS-CVOT (cardiovascular outcomes in type 2 diabetes)
Trial: A randomized, active-controlled cardiovascular outcomes trial of tirzepatide vs dulaglutide in adults with type 2 diabetes and high cardiovascular risk (NCT04255433).
Population: Adults with type 2 diabetes and established CVD or multiple CVD risk factors.
Primary endpoint: Time to first MACE-3.
Active comparator: Dulaglutide (Trulicity®), which itself demonstrated MACE benefit in REWIND (Lancet 2019).
As of May 2026, tirzepatide has demonstrated weight loss, A1C reduction, blood pressure reduction, and improvements in lipid profile and inflammatory markers in the SURMOUNT and SURPASS programs — all surrogate cardiovascular risk markers. The definitive MACE-reduction evidence is pending the SURMOUNT-MMO and SURPASS-CVOT readouts. The most relevant approved cardiovascular label currently belongs to semaglutide: Wegovy is FDA-approved (March 2024) for reduction of cardiovascular events in non-diabetic adults with overweight/obesity + established CVD based on SELECT.
Implications for prescribing today
For adults with type 2 diabetes + CVD: semaglutide (Ozempic) and dulaglutide both have demonstrated MACE benefit. Tirzepatide is approved for type 2 diabetes (Mounjaro) but has not yet demonstrated MACE benefit in a completed CVOT.
For non-diabetic adults with obesity + CVD: only semaglutide 2.4 mg (Wegovy) has demonstrated MACE benefit and a corresponding FDA label (March 2024).
For chronic weight management without established CVD: tirzepatide demonstrates the largest mean weight loss (20.9% at 15 mg / 72 weeks, SURMOUNT-1) among currently available GLP-1 and GIP/GLP-1 receptor agonists.
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $125 (6-mo, save $84) · $132 (3-mo, save $21) · $139 (monthly).
Includes: medication, all MD/DO visits, messaging (lab review under re-verification), personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Klarna & Affirm financing accepted at checkout (FAQ).
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
